To ask the Scottish Executive whether the recent Comment delivered by the Health Technology Board for Scotland (HTBS) on the National Institute of Clinical Excellence guidance for restricting the use of irinotecan, oxaliplatin and raltitrexed in the treatment of colorectal cancer is a valid judgement given that the remit of HTBS is to consider how the guidance should be applied in Scotland compared to England and Wales, that there is a higher level of colorectal cancer and poorer survival rate in Scotland and that patients in Scotland may be less likely to be fit for second-line therapy.